SALT LAKE CITY, Utah, March 12, 2026 (Bill’s Marketplace/Gephardt Daily)— A major shift is underway in the weight-loss medication market as Wegovy becomes the first pill form of semaglutide available in the United States. Medical professionals say the development could significantly expand access to treatment while lowering costs and removing common barriers that have kept some patients on the sidelines.
Dr. Joshua Schmidt, a Salt Lake-area physician with Prestige Men’s Health in Holladay, says the “oral option” represents a meaningful step forward for patients seeking medical weight loss without injections.
“It’s extremely promising,” Schmidt said. “There are a lot of patients who simply cannot or will not do injections — whether it’s fear of needles, coordination issues, or lifestyle concerns. Pill form opens the door for those patients.”
Schmidt’s team has long provided supervised weight-loss treatments using injectable semaglutide and other GLP-1 medications. But with oral semaglutide now available, the practice has begun offering pill-based options alongside those traditional injections.
“For those who are injection-averse, the psychological barrier alone can be enough to delay or avoid treatment entirely. Removing that obstacle is predicted to dramatically increase participation in this semaglutide-based weight-loss treatment, and that is good news for those looking to improve their overall health,” Schmidt said.
FDA approval of Wegovy in pill form
The U.S. Food and Drug Administration (FDA) approved the pill form of Wegovy on December 22, 2025. It hit the market in January. According to its manufacturer, Novo Nordisk, the new incarnation of the prescription drug also helps with chronic weight management in adults with obesity or overweight and is the first daily oral GLP-1 receptor agonist approved for weight loss. While specifically approved for weight loss, this oral formulation is also intended to reduce cardiovascular risks, similar to the injection.
Semaglutide therapies in injectable forms, including Ozempic, Wegovy, and Mounjaro, were first approved by the FDA in 2022. At the time of the approval, John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, said, “Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight. This patient population has a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.”
Convenience of Wegovy in pill form
One of the most immediate benefits of pill-form semaglutide is convenience, according to Schmidt. Unlike injectable versions, oral medications do not require refrigeration, making them easier to store, transport, and ship — particularly for patients who travel frequently.
“These medications are expensive, and refrigeration can be a real concern,” Schmidt explained. “With pills, there’s no cold storage requirement. If the power goes out, your medication isn’t ruined. That matters. And while final pricing details are still emerging, I fully expect oral semaglutide to be more affordable than injectable alternatives — another factor that could broaden access.”
“I suspect the price point will be lower than injections,” Schmidt said. “Between reduced manufacturing complexity, easier shipping, and no refrigeration, the overall cost structure should improve.”
Healthcare analysts believe that lower-cost GLP-1 options could have ripple effects across the healthcare industry, especially if broader adoption leads to population-wide reductions in obesity-related conditions.
“If we as a country lose even a small percentage of body weight,” Schmidt noted, “that translates to potentially dramatic savings across the entire healthcare spectrum — from heart disease to joint problems to diabetes management.”
Long-term semaglutide and staying power
As GLP-1 medications have surged in popularity, questions have surfaced about long-term effectiveness and whether patients must remain on the drugs indefinitely.
Schmidt says, from what he’s seen in his own practice, especially with non-diabetic patients, the answer is no.
“This is certainly not a lifelong medication for the vast majority of people,” he said. “Patients typically use it until they reach their weight-loss goals, then transition to lower maintenance doses or discontinue entirely. For diabetic patients, however, ongoing use may remain necessary for insulin management.”
Concerns about diminishing effectiveness over time, Schmidt believes, are often overstated. “In cases where patients plateau, we simply adjust the dose. We’ve seen patients on semaglutide for years, and it still works just as well as it did on day one.”
What expanded GLP-1 weight-loss treatment options mean for patients
With pill-form semaglutide entering the market, physicians expect increased competition, which should mean not just lower costs, but also greater normalization of medically supervised weight-loss solutions.
“This is great technology at its best,” Schmidt said. “The cheaper these medications become, and the easier they are to use, the more people we can help.”
As demand continues to grow, healthcare providers say the focus will remain on supervision, proper dosing, and long-term lifestyle changes — whether by pill or injection.
To read the results of the actual clinical study featured in The New England Journal of Medicine, click here.
To schedule a consultation with a Salt Lake City–area physician about Wegovy in pill form or other semaglutide options, contact Prestige Men’s Health in Holladay at (801) 695-4311.
Note: Prestige Men’s Health in Holladay is a sponsor of Bill’s Marketplace and proud supporter of independent local journalism.
